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Purpose. To evaluate potential risk factors for developing tube shunt exposure in glaucoma patients.Patients andMethods. Forty-one
cases from 41 patients that had tube shunt exposure from 1996 to 2005 were identified from the Robert Cizik Eye Clinic and Bascom
Palmer Eye Institute. Each case was matched with 2 controls of the same gender and with tube shunts implanted within 6 months
of the index case. Conditional logistic regression was used to determine risk factors. Results. The study cohort includes a total of 121
eyes from 121 patients.Themean age was 63.6± 19.7 years, ranging from 1 to 96 years.The average time to exposure was 19.29± 23.75
months (range 0.36–85.74 months). Risk factors associated with tube exposure were Hispanic ethnicity (𝑃 = 0.0115; OR= 3.6; 95%
CI, 1.3–9.7), neovascular glaucoma (𝑃 = 0.0064; OR= 28.5; 95%CI, 2.6–316.9), previous trabeculectomy (𝑃 = 0.0070; OR= 5.3; 95%
CI, 1.6–17.7), and combined surgery (𝑃 = 0.0381; OR= 3.7; 95%CI, 1.1–12.7).Conclusions. Hispanic ethnicity, neovascular glaucoma,
previous trabeculectomy, and combined surgery were identified as potential risk factors for tube shunt exposure. These potential
risk factors should be considered when determining the indication for performing tube shunt implantation and the frequency of
long-term followup.
1. Introduction
Tube shunts have historically been used to treat glaucoma
in cases that are refractory to filtering surgery or in those
where filtering surgery is unlikely to be successful. In recent
years, the indications have broadened, with some clinicians
advocating shunts as primary surgical treatment for advanced
glaucoma [1].The overall use of tube shunts has been steadily
increasing over the past decade, with one study showing an
annual increase in the number of shunts placed between
the years of 1995 and 2004 totaling 184% [2]. These devices
function by draining aqueous through a silicone tube to
a reservoir plate, which is covered by Tenon’s capsule and
conjunctiva. The tube is generally covered by one of a variety
of patch materials where it enters the eye to prevent exposure
through the overlying tissue. Such exposures may lead to
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more serious complications, such as endophthalmitis, if not
promptly identified and treated [3].
The Tube versus Trabeculectomy and Ahmed Baerveldt
Comparison studies reported the incidence of tube exposure
as 5% at 5 years of followup and 1% at 1 year of followup,
respectively [4, 5]. The specific causes of tube exposure,
however, have not been clearly elucidated in the literature.
Byun et al. concluded that the number of previous ocular
surgeries may be a risk factor for tube exposure [6]. Although
Huddleston et al. examined risk factors for failure of repair of
tube shunt exposures [7], we are unaware of previous reports
in the literature evaluating risk factors for developing tube
shunt exposures.
The purpose of this study was to evaluate potential risk
factors for developing tube shunt exposures in glaucoma
patients.
2. Patients and Methods
Aretrospectivematched case-control studywas conducted by
reviewing charts from the Robert Cizik Eye Clinic at the Ruiz
Department of Ophthalmology and Visual Science at The
University of Texas Medical School in Houston (UTH) and
the Bascom Palmer Eye Institute (BPEI) at the Miller School
of Medicine, University of Miami. The Institutional Review
Boards (IRBs) from each institution determined that this
study was exempt for IRB review prior to initiation. Patient
information was collected from charts using uniform data
collection sheets in full compliance with HIPPA regulations.
All research methods were in compliance with the Declara-
tion of Helsinki and all federal and state laws of the United
States.
Potential cases were identified using a computerized
search of current procedural terminology (CPT) codes for
repair of glaucoma drainage device between the years of 1996
and 2005 and were included in the study if the reason for
repair was tube shunt exposure. Two controls were matched
to each case based on implantation of a glaucoma drainage
device within 6 months of implantation of the corresponding
case. Controls were also matched to cases based on gender.
Data collected included demographics (age, race/ethnic-
ity (self-reported), and gender) and presence of comorbid
conditions (diabetes, hypertension, and history of auto-
immune diseases). Baseline ocular information collected
included the type of glaucoma, number of intraocular-
pressure- (IOP-) lowering medications at the visit prior to
initial implantation of tube shunt, number and type of prior
glaucoma surgeries, and IOP. Number and type of previous
ocular surgeries were also collected. Details of the technique
of tube shunt implantation were recorded, including type
of drainage device, device location, tube entry site, patch
graft material, and whether or not it was combined with
another surgical intervention. Date of diagnosis of exposure
was also recorded. Data collected from each institution were
combined into a unified data set.
Descriptive statistics, mean and standard deviation, were
calculated for continuous variables, that is, age, IOP, and
so forth, and frequency and percentage were calculated for
discrete variables, that is, gender, race, primary diagnosis,
and so forth. The two-sample t-test or the Fisher exact test
was used to compare groups. A stepwise conditional logistic
regression was used to identify risk factors associated with
tube exposure through the conjunctiva.Themodel contained
an outcome variable, tube exposure (yes/no), and risk factors,
including center (UTH versus BPEI), age, ethnicity (Hispanic
versus non-Hispanic), history of diabetes mellitus, history
of hypertension, history of autoimmune disease, type of
glaucoma (neovascular (NVG) versus others), number of top-
ical glaucoma medications used before shunt implantation,
number of previous ocular surgeries (3 or more versus less
than 3), previous tube implantation, previous trabeculectomy
surgery, previous glaucoma laser surgery, previous retinal
surgery, previous vitrectomy, shunt implantation combined
with other surgery, and tube location. A risk factor was
selected if the 𝑃 value was less than 0.15 and was removed
if 𝑃 value > 0.05.
The analyses were performed using SAS v9.2 (SAS Insti-
tute, Inc., Cary, NC). 𝑃 values < 0.05 were considered
statistically significant. 𝑃 values were obtained from the two-
sample t-test for continuous variables, Fisher exact test for
discrete variables, and from the stepwise conditional logistic
regression for risk factors. 𝑃 values < 0.05 were considered
statistically significant.
3. Results
A total of 41 cases from 41 patients were identified, 17 from
UTH and 24 from BPEI. Each case was matched with 2
controls. Two cases from BPEI were only matched with
one control due to lack of appropriate matches within the
specified time frame. Thus, the study cohort included a total
of 121 eyes from 121 patients, 51 eyes from UTH and 70 from
BPEI. Thirty-eight patients (31.4%) were black, 37 (30.6%)
were Hispanic, 44 (36.4%) were white, and 2 were Asian.
Seventy-three (60.3%) were women.Themean age was 63.6±
19.7 years, ranging from 1 to 96 years.Thirty patients (24.8%)
had diabetes mellitus, and 48 (39.7%) had hypertension. The
average time to exposure was 19.29 ± 23.75 months (range
0.36–85.74 months).
For the case group, the time to exposure was bimodally
distributed with an average of 19.29 ± 23.75 months (range
0.36–85.74 months), while in the control group, the follow-
up duration was approximately normally distributed with an
average of 56.60 ± 38.02months (range 0.303–161.1 months).
In the exposure (cases) group, 33 patients (80%) had tube
exposures, while 7 (17%) had plate exposures; one was
unknown.
Data were evaluated on the potential risk factors as
described earlier in Section 2. There were not enough
cases/controls to evaluate the effect of autoimmune diseases
(1 case, 2 controls) or inferior versus superior location. Table 1
summarizes demographics and preoperative characteris-
tics before undergoing initial tube shunt implantation and
tube shunt implantation parameters for each group. The
Fisher exact test found statistically significant differences in
race/ethnicity (𝑃 = 0.015), type of glaucoma (𝑃 = 0.0235),
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Table 1: Demographics/preoperative glaucoma patient characteristics and tube shunt implantation parameters.
Variable Cases Controls 𝑃 valuea
Center, no. of cases/controls (%) 1.000
BPEI 24 (58.5) 46 (57.5)
UTH 17 (41.5) 34 (42.5)
Demographics
Sex (female, %)b 25 (61.0) 48 (60.0) 1.000
Race/ethnicity, no. of patients (%) 0.015c
White 12 (29.3) 32 (40.0)
Black 9 (22.0) 29 (36.3)
Hispanic 20 (48.8) 17 (21.3)
Asian 0 (0.0) 2 (2.5)
Age, mean years (SD) 64.2 (19.1) 63.6 (20.2) 0.8713
Comorbid systemic diseases
Diabetes, no. of eyes (%) 12 (29.3) 18 (22.5) 0.5054
Hypertension, no. of eyes (%) 17 (41.5) 31 (38.8) 0.8452
Baseline ocular information (before shunt implantation)
Type of glaucoma, no. of eyes (%) 0.0235c
Primary open angle glaucoma 11 (26.8) 38 (47.5)
Neovascular glaucoma (NVG) 9 (22.0) 6 (7.5)
Others 21 (51.2) 36 (45.0)
Preoperative intraocular pressure, mean mmHg (SD) 30.8 (11.2) 29.9 (10.1) 0.6573
No. of IOP-lowering medications, mean (SD) 2.1 (1.0) 2.3 (1.1) 0.4369
Previous trabeculectomy, no. of eyes (%) 21 (51.2) 26 (32.9)d 0.0753
Previous tube shunt implantation, no. of eyes (%) 4 (9.8) 3 (3.3) 0.2285
Previous laser procedure (ALT), no. of eyes (%) 3 (7.3) 6 (7.7)e 1.000
Previous PK/PKP, no. of eyes (%) 4 (9.8) 6 (7.5) 0.7324
Previous PRP/EL, no. of eyes (%) 15 (36.6) 6 (7.7)e 0.0002c
Previous vitrectomy, no. of eyes (%) 9 (22.0) 9 (11.3) 0.1755
Previous ocular surgeries, no. of eyes 3 or more (%) 24 (58.5) 22 (27.5) 0.0014c
Tube shunt implantation parameters
Type of shunt device, no. of Baerveldt (%) 40 (97.6) 77 (96.3) 1.000
Device location, no. of superotemporal (%) 40 (97.6) 73 (91.3) 0.2633
Tube entry site, no. of anterior chambers (%) 28 (92.7) 74 (92.5) 1.000
Type of patch graft used, no. of scleral patch grafts (%) 29 (70.7) 26 (62.5) 0.3416
Combined surgery, no. of eyes (%) 16 (39.0) 19 (19.8) 0.0928
Combined with cataract, no. of eyes (%) 6 (14.6) 12 (15.0) 1.000
Combined with PKP, no. of eyes (%) 2 (4.9) 1 (1.3) 0.2648
Combined with vitrectomy, no. of eyes (%) 9 (13.0) 10 (12.5) 0.1945
BPEI: Bascom Palmer Eye Institute; UTH: The University of Texas Medical School at Houston; NVG: neovascular glaucoma; PKP: penetrating keratoplasty;
ALT: argon laser trabeculoplasty; PK: penetrating keratectomy; PRP: panretinal photocoagulation; EL: endolaser; SD: standard deviation; No.: number.
aObtained from two-sample 𝑡-test for continuous variables and Fisher exact test for discrete variables.
bSex was used to match cases to controls.
cStatistically significant, 𝑃 < 0.05.
dOne missing observation.
eTwo missing observations.
Note: 5 eyes combined with both cataract and vitrectomy (1 case, 4 controls).
prior panretinal photocoagulation (PRP; 𝑃 = 0.0002), and 3
or more ocular surgeries prior to the tube implantation (𝑃 =
0.0014). Of the 15 NVG eyes, 7 had PRP procedures prior
to shunt implantation; 5 of these had shunt exposure later.
The percentage of eyes having 3 or more surgical procedures
done before shunt implantation was significantly higher in
cases than in controls (58.8% cases versus 27.0% controls;
𝑃 = 0.0014).
Using a stepwise conditional logistic regression, risk
factors associated with tube exposure were Hispanic
ethnicity (𝑃 = 0.0115; odds ratio (OR) = 3.6; 95% confidence
interval (CI), 1.3–9.7), NVG (𝑃 = 0.0064; OR = 28.5; 95% CI,
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Table 2: Risk factors associated with tube exposure.
Risk factor 𝛽 ± SE Odds ratio 𝑃 value 95% confidence interval
Hispanic ethnicity 1.28 ± 0.51 3.6 0.0115 1.3–9.7
Neovascular glaucoma 3.35 ± 1.23 28.5 0.0064 2.6–316.9
Previous trabeculectomy 1.66 ± 0.62 5.3 0.0070 1.6–17.7
Combined surgery 1.31 ± 0.63 3.7 0.0381 1.1–12.7
𝛽 ± SE: estimated parameter from the conditional logistic regression model with standard error.
2.6–316.9), previous trabeculectomy (𝑃 = 0.0070; OR = 5.3;
95% CI, 1.6–17.7), and combined surgery (𝑃 = 0.0381; OR =
3.7; 95% CI, 1.1–12.7). Hispanics eyes experienced 3.6 times
higher risk of tube exposure than non-Hispanics; NVG eyes
experienced nearly 30 times higher risk than other types
of glaucoma eyes. Eyes that had previous trabeculectomy
increased the risk of exposure about 5 times, and combined
tube implantation surgeries with other surgeries also
increased the risk of exposure about 4 times (Table 2).
4. Discussion
Tube shunt exposure is an infrequent complication, which
may explain the paucity of the literature on the subject. To
the best of our knowledge, this is the first controlled study
evaluating potential risk factors for tube shunt exposure.
The vast majority of tube shunts were Baerveldt Glaucoma
Implants (Abbott Medical Optics, Inc., Santa Ana, CA) in
this study (most likely due to surgeon preference or patient
necessity), and there has been no study evaluating risk factors
for this complication in Baerveldt shunts.There are, however,
a few proposed theories on the etiology of tube shunt
exposure. Lankaranian et al. suggested that the mechanical
forces of the eyelid as well as the pressure of the underlying
tube may contribute to conjunctival exposures [1, 8], while
Smith et al. proposed both mechanical and immunologic
factors contributing [9]. The intention of the current study
was to examine the potential factors which might predispose
to exposure based on the previous theories. Unfortunately,
our numbers of patients with autoimmune diseases and
inferiorly placed shunts were few, and there was not adequate
power to evaluate their impact.
In the only similar study by Byun et al., AhmedGlaucoma
Valves (New World Medical, Inc., Rancho Cucamonga, CA)
were examined in a total of 11 cases of conjunctival exposure.
The authors of this study concluded that the only risk factor
for exposure was the number of previous ocular surgeries.
They concluded that NVG was not a risk factor for exposure,
and ethnicity was not a variable that was considered, as all of
the patients appear to have been of Korean descent [6].
In our study, Hispanic patients had a higher incidence
of tube exposure than non-Hispanics [7]. It is unclear why
Hispanics would have a higher incidence of exposures than
non-Hispanics; however, it is possible that there are socioeco-
nomic factors that cannot be elucidated by the data collected
in this retrospective study.TheHispanics in the 2 locations are
also potentially ancestrally distinct. Elucidating the finding
that Hispanics were at higher risk of tube exposure was likely
only possible because both sites have a high proportion of
patients who are ethnically Hispanic [10].
Neovascular glaucoma (NVG) was also found to be a risk
factor for tube shunt exposure. The most common cause of
NVG in this population was diabetes mellitus, and a large
proportion of the patients in this study with NVG also had
diabetic retinopathy (8 of the 15 with NVG). Diabetics are
known to have vascular changes in the conjunctiva similar
to those found in the retina, suggesting that there is poor
conjunctival perfusion [11], which may theoretically result in
less tissue modulation and poorer tissue strength. Prior PRP
was more common in cases than controls in this study, with
15 (36.6%) cases and only 6 (7.7%) controls having had prior
treatment with PRP. However, this effect did not appear in
the multivariate analysis. This suggests that the relationship
between PRP and tube shunt exposures is more likely a
relationship between the underlying disease (NVG), which
required the PRP, and tube shunt exposure than the PRP itself.
As there is an elevated rate of diabetes in Hispanic popu-
lations [10] and with neovascular glaucoma also found to be a
risk factor in this study, there may be a potential relationship
to be elucidated between these 3 factors. However, there were
only 8 patients with diabetes and neovascular glaucoma and
only 2 of those were Hispanic (both in case group; none in
control group); these small numbers make it difficult to draw
conclusions on this relationship.
Prior trabeculectomywas found to be a risk factor for tube
shunt exposure. The data collected for this study came from
patients with tube shunt implantation between the years of
1996 and 2005, a time when mitomycin-C and 5-fluorouracil
were frequently used to modulate wound healing in tra-
beculectomies at both BPEI and UTH, as well as many other
clinical practices. The long-term results of aggressive use of
these antifibrotic agents have been to increase the numbers of
bleb breakdowns andwound leaks [12]. A similar process that
resulted in ischemic blebs and bleb breakdown could result
in late tube shunt exposures. This is likely a true risk factor
because the interaction effect of previous trabeculectomies
and multiple previous surgeries was not significant (𝑃 =
0.1916) in the conditional logistic regression.The relationship
between antifibrotic regimen used in trabeculectomy and
later tube shunt exposure cannot be evaluated due to a lack
of trabeculectomies being performed during that time frame
at these 2 institutions without the use of these agents. Thus
the health of the conjunctiva after trabeculectomy may be an
important factor in the prevention of tube exposures.
Another risk factor for tube shunt exposure was tube
shunt implantation combined with another surgery, most
often cataract surgery or vitrectomy. Cataract surgery is
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commonly performed in combination with tube shunt
implantation because of the possibility of progression of
cataract after tube shunt implantation in a phakic eye [13]. It
is possible that the technique of tube shunt positioning was
altered to be combined with another surgery. The operative
reports were not useful to delineate such a difference. Com-
bining tube shunt implantation with vitrectomy is generally
performed in complicated cases with poor underlying tissue
health, such as in neovascular eyes, uveitic eyes, or in cases
of intended pars plana placement (i.e., eyes with preexisting
penetrating keratoplasty). Thus, implant positioning alone
may not be solely responsible for this increased risk.
Based on the results of this study, it appears that a number
of different risk factors may increase the risk of tube shunt
exposure. Co-morbid medical conditions, such as diabetes,
that lead to ischemia of ocular tissues appear to be an
important factor to consider in patients with this surgery.
The ocular surgical history also plays a significant role in
the ability to successfully cover the tube. One weakness of
this study is the retrospective nature of data collection, which
prevents useful evaluation of potential risk factors which are
not available in the data set.
The majority of tube shunts in this study were of the
Baerveldt variety (97.6% and 96.3% in cases and controls,
resp.), which limited the ability of this study to evaluate the
different types of tube shunts. The majority of patch graft
material used in both cases and controls was sclera (70.7%
and 62.5%, resp.), which also limited the ability of the study to
compare the different types of patch graftmaterial in a similar
way. Although we intended to look at graft type as a potential
risk factor, the study was underpowered to determine any
useful finding.
In conclusion, this study identified Hispanic ethnicity,
neovascular glaucoma, prior trabeculectomy, and combined
surgery as potential risk factors for tube shunt exposure.
These risk factors should be considered when determining
the indication for performing tube shunt implantation and
the frequency of long-term followup.
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